Neurobiological Technologies, Inc. (NASDAQ: NTII) is a biopharmaceutical company focused on developing innovative and leading agents for central nervous system conditions and other serious medical conditions. The company seeks out drug candidates related to the central nervous system, and develops therapies for neurological conditions that occur in connection with dementia, Alzheimer’s disease, ischemic stroke, neuropathic pain, and brain cancer. They employ a strategy of in-licensing late-stage CNS agents and strive to gain regulatory approval and commercialization, either independently or with a strategic partner.

Neurobiological Technologies most advanced product candidate is Viprinexâ„¢ (ancrod), a drug for treating acute ischemic stroke. The product is in Phase 3 of clinical testing as a novel investigational drug with multiple mechanisms of action that are specifically designed to double the time period that patients can be treated after the onset of a stroke. Acute ischemic stroke is one of the most common, invigorating, and costly diseases in the world, for which there are few acceptable treatment options. NTI’s pipeline also includes a phase 3 investigational drug for brain swelling and other drug candidates in early-stage development for Alzheimer’s and Huntington’s diseases.

The company’s other two products include XERECEPT and MEMANTINE (Namenda®). XERECEPT is an original agent being investigated for the treatment of brain swelling associated with brain tumors, and possesses the potential to enhance in functional independence and reduction in required level of care. Currently, the drug is being tested in two pivotal Phase III clinical studies, which are taking place in the United States and Canada. MEMANTINE (Namenda®) will be used to combat moderate to severe dementia and Alzheimer’s disease. NTI has an exclusive marketing arrangement that states they have the right to receive royalty payments from Merz and their marketing partners.

Let us hear your thoughts: Neurobiological Technologies, Inc. Message Board

Last 5 posts by QualityStocks

• Prime Sun Power, Inc. (PSPW.OB) Up 170% After Recent QualityStocks Newsletter Coverage - February 9th, 2010
• SANUWAVE Health Inc.’s (SNWV.OB) Burn Treatment Device Receives Positive Review in Industry Publication - February 9th, 2010
• Prime Sun Power, Inc. (PSPW.OB) Pushes Photovoltaic Solar in European Market - February 9th, 2010
• WikiLoan, Inc. (WKLI.OB) Initiates Marketing Campaign - February 9th, 2010
• eDoorways Corp. (EDWY.PK) Sales Efforts Led by Retail Marketing Expert - February 9th, 2010